Alison R. Sehgal

6.5k total citations
52 papers, 1.1k citations indexed

About

Alison R. Sehgal is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Alison R. Sehgal has authored 52 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 18 papers in Hematology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Alison R. Sehgal's work include CAR-T cell therapy research (29 papers), Lymphoma Diagnosis and Treatment (16 papers) and Acute Myeloid Leukemia Research (15 papers). Alison R. Sehgal is often cited by papers focused on CAR-T cell therapy research (29 papers), Lymphoma Diagnosis and Treatment (16 papers) and Acute Myeloid Leukemia Research (15 papers). Alison R. Sehgal collaborates with scholars based in United States, France and Germany. Alison R. Sehgal's co-authors include Michael Boyiadzis, Annie Im, Martin Carroll, Daniel E. Johnson, B. Douglas Smith, Ayalew Tefferi, Theresa L. Whiteside, David G. Maloney, Jeremy S. Abramson and Charalambos Andreadis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alison R. Sehgal

47 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison R. Sehgal United States 13 633 373 326 227 174 52 1.1k
Benoît Tessoulin France 18 516 0.8× 436 1.2× 365 1.1× 219 1.0× 306 1.8× 79 1.2k
Quanshun Wang China 10 755 1.2× 285 0.8× 176 0.5× 245 1.1× 142 0.8× 63 1.0k
Connie Lee Batlevi United States 17 763 1.2× 270 0.7× 87 0.3× 198 0.9× 450 2.6× 83 1.1k
Kathleen Dorritie United States 15 466 0.7× 166 0.4× 179 0.5× 216 1.0× 149 0.9× 45 773
Sherilyn A. Tuazon United States 10 494 0.8× 476 1.3× 517 1.6× 128 0.6× 63 0.4× 27 941
Zaid Al‐Kadhimi United States 18 540 0.9× 182 0.5× 425 1.3× 337 1.5× 82 0.5× 84 1.0k
Michel Delforge Belgium 17 509 0.8× 486 1.3× 716 2.2× 113 0.5× 81 0.5× 111 1.0k
Christopher Hunt Keir United States 12 613 1.0× 326 0.9× 115 0.4× 137 0.6× 40 0.2× 25 867
Irene Pizzitola Italy 11 718 1.1× 350 0.9× 285 0.9× 654 2.9× 34 0.2× 17 1.2k
Abdul Hamid Bazarbachi United States 14 479 0.8× 388 1.0× 550 1.7× 153 0.7× 86 0.5× 30 878

Countries citing papers authored by Alison R. Sehgal

Since Specialization
Citations

This map shows the geographic impact of Alison R. Sehgal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison R. Sehgal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison R. Sehgal more than expected).

Fields of papers citing papers by Alison R. Sehgal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison R. Sehgal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison R. Sehgal. The network helps show where Alison R. Sehgal may publish in the future.

Co-authorship network of co-authors of Alison R. Sehgal

This figure shows the co-authorship network connecting the top 25 collaborators of Alison R. Sehgal. A scholar is included among the top collaborators of Alison R. Sehgal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison R. Sehgal. Alison R. Sehgal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ghosh, Nilanjan, Alison R. Sehgal, Fei‐Fei Liu, et al.. (2024). Comparative efficacy of lisocabtagene maraleucel in the PILOT study <i>versus</i> second-line chemotherapy regimens in the real world. Haematologica. 110(3). 693–705. 1 indexed citations
2.
Gordon, Leo I., Fei‐Fei Liu, Julia Braverman, et al.. (2023). Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica. 109(3). 857–866. 6 indexed citations
3.
4.
5.
Abramson, Jeremy S., M. Lia Palomba, Leo I. Gordon, et al.. (2021). Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). Blood. 138(Supplement 1). 2840–2840. 40 indexed citations
6.
Samanta, Palash, et al.. (2020). 1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications. Open Forum Infectious Diseases. 7(Supplement_1). S583–S583. 4 indexed citations
7.
Resick, Judith, Robert M. Arnold, Thomas W. LeBlanc, et al.. (2020). Primary Palliative Care for Patients with Advanced Hematologic Malignancies: A Pilot Trial of the SHARE Intervention. Journal of Palliative Medicine. 24(6). 820–829. 11 indexed citations
8.
Ujjani, Chaitra S., Anthony R. Mato, Brian T. Hill, et al.. (2020). <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. SHILAP Revista de lepidopterología. Volume 10. 1–5. 6 indexed citations
9.
Abramson, Jeremy S., Maria Lia Palomba, Leo I. Gordon, et al.. (2019). Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood. 134(Supplement_1). 241–241. 89 indexed citations
10.
Redner, Robert L., Jan H. Beumer, Patricia Kropf, et al.. (2018). A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia & lymphoma. 59(11). 2595–2601. 10 indexed citations
11.
Lontos, Konstantinos, Mounzer Agha, Anastasios Raptis, et al.. (2017). Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation. Clinical Transplantation. 31(9). 1 indexed citations
12.
Boyiadzis, Michael, Mounzer Agha, Robert L. Redner, et al.. (2017). Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 19(10). 1225–1232. 139 indexed citations
13.
Agha, Mounzer, Anastasios Raptis, Jing‐Zhou Hou, et al.. (2016). Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfusion and Apheresis Science. 55(2). 216–220. 20 indexed citations
14.
Sloan, Caroline E., Marlise R. Luskin, Alison R. Sehgal, et al.. (2016). A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS ONE. 11(4). e0153016–e0153016. 9 indexed citations
15.
Sehgal, Alison R., Phyllis A. Gimotty, Jianhua Zhao, et al.. (2015). DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia. Clinical Cancer Research. 21(7). 1614–1620. 39 indexed citations
16.
Raptis, Anastasios, Jing‐Zhou Hou, Rafic Farah, et al.. (2015). Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant. European Journal Of Haematology. 96(1). 55–59. 1 indexed citations
17.
Sehgal, Alison R., Theresa L. Whiteside, & Michael Boyiadzis. (2015). Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opinion on Biological Therapy. 15(8). 1191–1203. 51 indexed citations
18.
Im, Annie, Alison R. Sehgal, Martin Carroll, et al.. (2014). DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 28(9). 1774–1783. 193 indexed citations
19.
Sehgal, Alison R., Helmut König, D E Johnson, et al.. (2014). You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia. 29(3). 517–525. 75 indexed citations
20.
Bagley, Stephen, Alison R. Sehgal, Saar Gill, et al.. (2014). Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition. Biology of Blood and Marrow Transplantation. 21(4). 768–771. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Benoît Tessoulin Breakdown of academic impact, for papers by Quanshun Wang Breakdown of academic impact, for papers by Connie Lee Batlevi Breakdown of academic impact, for papers by Kathleen Dorritie Breakdown of academic impact, for papers by Sherilyn A. Tuazon Breakdown of academic impact, for papers by Zaid Al‐Kadhimi Breakdown of academic impact, for papers by Michel Delforge Breakdown of academic impact, for papers by Christopher Hunt Keir Breakdown of academic impact, for papers by Irene Pizzitola Breakdown of academic impact, for papers by Abdul Hamid Bazarbachi
Rankless by CCL
2026